Jared Sivinski1, Andrew J Ambrose1, Iliya Panfilenko1, Christopher J Zerio1, Jason M Machulis1, Niloufar Mollasalehi2,3,4, Lynn K Kaneko1, Mckayla Stevens5, Anne-Marie Ray5, Yangshin Park5,6,7, Chunxiang Wu5,6,7, Quyen Q Hoang5,6,7, Steven M Johnson5, Eli Chapman8. 1. Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, USA. 2. Department of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona, USA. 3. Center for Innovation in Brain Science, Tucson, Arizona, USA. 4. Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA. 5. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA. 6. Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA. 7. Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA. 8. Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, USA chapman@pharmacy.arizona.edu.
Abstract
As the GroES/GroEL chaperonin system is the only bacterial chaperone that is essential under all conditions, we have been interested in the development of GroES/GroEL inhibitors as potential antibiotics. Using Escherichia coli GroES/GroEL as a surrogate, we have discovered several classes of GroES/GroEL inhibitors that show potent antibacterial activity against both Gram-positive and Gram-negative bacteria. However, it remains unknown if E. coli GroES/GroEL is functionally identical to other GroES/GroEL chaperonins and hence if our inhibitors will function against other chaperonins. Herein we report our initial efforts to characterize the GroES/GroEL chaperonins from clinically significant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). We used complementation experiments in GroES/GroEL-deficient and -null E. coli strains to report on exogenous ESKAPE chaperone function. In GroES/GroEL-deficient (but not knocked-out) E. coli, we found that only a subset of the ESKAPE GroES/GroEL chaperone systems could complement to produce a viable organism. Surprisingly, GroES/GroEL chaperone systems from two of the ESKAPE pathogens were found to complement in E. coli, but only in the strict absence of either E. coli GroEL (P. aeruginosa) or both E. coli GroES and GroEL (E. faecium). In addition, GroES/GroEL from S. aureus was unable to complement E. coli GroES/GroEL under all conditions. The resulting viable strains, in which E. coli groESL was replaced with ESKAPE groESL, demonstrated similar growth kinetics to wild-type E. coli, but displayed an elongated phenotype (potentially indicating compromised GroEL function) at some temperatures. These results suggest functional differences between GroES/GroEL chaperonins despite high conservation of amino acid identity.IMPORTANCE The GroES/GroEL chaperonin from E. coli has long served as the model system for other chaperonins. This assumption seemed valid because of the high conservation between the chaperonins. It was, therefore, shocking to discover ESKAPE pathogen GroES/GroEL formed mixed-complex chaperonins in the presence of E. coli GroES/GroEL, leading to loss of organism viability in some cases. Complete replacement of E. coli groESL with ESKAPE groESL restored organism viability, but produced an elongated phenotype, suggesting differences in chaperonin function, including client specificity and/or refolding cycle rates. These data offer important mechanistic insight into these remarkable machines, and the new strains developed allow for the synthesis of homogeneous chaperonins for biochemical studies and to further our efforts to develop chaperonin-targeted antibiotics.
As the GroES/pan class="Gene">GroEL chaperonin system is the only bacterial chaperone that is essential under all conditions, we have been interested in the development of GroES/GroEL inhibitors as potential antibiotics. Using Escherichia coliGroES/GroEL as a surrogate, we have discovered several classes of GroES/GroEL inhibitors that show potent antibacterial activity against both Gram-positive and Gram-negative bacteria. However, it remains unknown if E. coliGroES/GroEL is functionally identical to other GroES/GroEL chaperonins and hence if our inhibitors will function against other chaperonins. Herein we report our initial efforts to characterize the GroES/GroEL chaperonins from clinically significant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). We used complementation experiments in GroES/GroEL-deficient and -null E. coli strains to report on exogenous ESKAPE chaperone function. In GroES/GroEL-deficient (but not knocked-out) E. coli, we found that only a subset of the ESKAPE GroES/GroEL chaperone systems could complement to produce a viable organism. Surprisingly, GroES/GroEL chaperone systems from two of the ESKAPE pathogens were found to complement in E. coli, but only in the strict absence of either E. coliGroEL (P. aeruginosa) or both E. coliGroES and GroEL (E. faecium). In addition, GroES/GroEL from S. aureus was unable to complement E. coliGroES/GroEL under all conditions. The resulting viable strains, in which E. coligroESL was replaced with ESKAPE groESL, demonstrated similar growth kinetics to wild-type E. coli, but displayed an elongated phenotype (potentially indicating compromised GroEL function) at some temperatures. These results suggest functional differences between GroES/GroEL chaperonins despite high conservation of amino acid identity.IMPORTANCE The GroES/GroEL chaperonin from E. coli has long served as the model system for other chaperonins. This assumption seemed valid because of the high conservation between the chaperonins. It was, therefore, shocking to discover ESKAPE pathogen GroES/GroEL formed mixed-complex chaperonins in the presence of E. coliGroES/GroEL, leading to loss of organism viability in some cases. Complete replacement of E. coligroESL with ESKAPE groESL restored organism viability, but produced an elongated phenotype, suggesting differences in chaperonin function, including client specificity and/or refolding cycle rates. These data offer important mechanistic insight into these remarkable machines, and the new strains developed allow for the synthesis of homogeneous chaperonins for biochemical studies and to further our efforts to develop chaperonin-targeted antibiotics.
Authors: H R Saibil; D Zheng; A M Roseman; A S Hunter; G M Watson; S Chen; A Auf Der Mauer; B P O'Hara; S P Wood; N H Mann; L K Barnett; R J Ellis Journal: Curr Biol Date: 1993-05-01 Impact factor: 10.834
Authors: C M Santosh Kumar; Garima Khare; C V Srikanth; Anil K Tyagi; Abhijit A Sardesai; Shekhar C Mande Journal: J Bacteriol Date: 2009-08-28 Impact factor: 3.490
Authors: Jared Sivinski; Duc Ngo; Christopher J Zerio; Andrew J Ambrose; Edmond R Watson; Lynn K Kaneko; Marius M Kostelic; Mckayla Stevens; Anne-Marie Ray; Yangshin Park; Chunxiang Wu; Michael T Marty; Quyen Q Hoang; Donna D Zhang; Gabriel C Lander; Steven M Johnson; Eli Chapman Journal: FASEB J Date: 2022-03 Impact factor: 5.191